Beta

Mink therapeutics, inc.INKT.US Overview

US StockHealthcare
(No presentation for INKT)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

INKT AI Insights

INKT Overall Performance

INKT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

INKT Recent Performance

-2.33%

Mink therapeutics, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

INKT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check INKT's Trend

INKT Key Information

INKT Valuation Metrics

INKT Profile

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Price of INKT

INKT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.52
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
11.33
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-2.52
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
11.33
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is INKT's latest earnings report released?

    The most recent financial report for Mink therapeutics, inc. (INKT) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating INKT's short-term business performance and financial health. For the latest updates on INKT's earnings releases, visit this page regularly.

  • How much cash does INKT have?

    At the end of the period, Mink therapeutics, inc. (INKT) held Total Cash and Cash Equivalents of 13.36M, accounting for 0.94 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is INKT's EPS continuing to grow?

    According to the past four quarterly reports, Mink therapeutics, inc. (INKT)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.54. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of INKT?

    Mink therapeutics, inc. (INKT)'s Free Cash Flow (FCF) for the period is -2.07M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 20.03% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of INKT?

    The latest valuation data shows Mink therapeutics, inc. (INKT) has a Price-To-Earnings (PE) ratio of -4.19 and a Price/Earnings-To-Growth (PEG) ratio of 0.3. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.

INKT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1